Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination